{"filing":{"accession_number":"0001140361-26-034700","cik":"0001697862","ticker":"ARGX","company_name":"ARGENX SE","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ef20081196_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_6k.htm"},"events":[{"id":30054,"run_id":27548,"accession_number":"0001140361-26-034700","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This exhibit announces the successful completion of argenx's acquisition of Forte Biosciences, Inc. for $77.00 per share in cash through a tender offer and merger. The transaction adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline. This is a material acquisition that expands the company's product portfolio and represents a significant strategic transaction that would affect a reasonable investor's assessment of argenx's business and future prospects.","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":[{"id":32552,"accession_number":"0001140361-26-034700","item_number":"EX-99.1","item_title":"ef20081196_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This exhibit announces the successful completion of argenx's acquisition of Forte Biosciences, Inc. for $77.00 per share in cash through a tender offer and merger. The transaction adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline. This is a material acquisition that expands the company's product portfolio and represents a significant strategic transaction that would affect a reasonable investor's assessment of argenx's business and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:21:07.327773+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32552,"accession_number":"0001140361-26-034700","item_number":"EX-99.1","item_title":"ef20081196_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This exhibit announces the successful completion of argenx's acquisition of Forte Biosciences, Inc. for $77.00 per share in cash through a tender offer and merger. The transaction adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline. This is a material acquisition that expands the company's product portfolio and represents a significant strategic transaction that would affect a reasonable investor's assessment of argenx's business and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:21:07.327773+00:00","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-08-27"}]}